Condition: Bone and Soft Tissue Tumors · Sponsor: Istituto Ortopedico Rizzoli
DEEPLY aims to improve sarcoma therapy by the development of an innovative nanophotonic delivery approach to be applied in the future as an integrated local therapy for patients with inoperable tumors or with oligometastases. The major aim of the project is the development of innovative nanocarriers loaded with chemotherapeutic agents, whose delivery will be improved by the use of an optic fiber (optoporation). After the synthesis, and characterization of NPs, a prototype will be produced and preclinically validated on patient-derived biological material. This wide comprehensive methodological approach will ensure the obtainment of robust data to be faster exploited toward clinical applications.
This description comes directly from the study's public registry record.
Toni Ibrahim, MD Oncologist · +39 0516366199 · toni.ibrahim@ior.it
Always discuss trial participation with your own doctor first.
| Istituto Ortopedico Rizzoli-OSOTT | Bologna, Emilia-Romagna, Italy | Recruiting |
| IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori | Meldola, Emilia-Romagna, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06599957